What is COFEPRIS?
COFEPRIS — the Comisión Federal para la Protección contra Riesgos Sanitarios — is Mexico's federal health authority. It is the Mexican equivalent of the FDA in the United States: a regulatory agency operating under the Secretaría de Salud (Ministry of Health) that controls medical devices, drugs, biologics, food safety, advertising of health services, and the licensing of medical establishments.
Any clinic that offers regenerative medicine in Mexico — including stem cell therapy, exosome therapy, peptide protocols, or PRP — is required to operate under at least two COFEPRIS authorizations: an Aviso de Funcionamiento (operating notice) tied to the physical establishment, and an Aviso de Publicidad (advertising notice) tied to the way the services are described to the public. Sourcing of biological products is regulated through additional COFEPRIS routes for tissue banks, blood banks, and the laboratories that manufacture cellular preparations.
Regulatory facts at a glance
Short, citation-ready summary of how Mexico regulates stem cell therapy.
- COFEPRIS authority
- COFEPRIS is Mexico's federal health authority — the regulatory equivalent of the U.S. FDA — operating under the Secretaría de Salud and responsible for authorizing medical establishments, laboratories, biologics, and health advertising.
- FDA vs COFEPRIS
- The FDA regulates the cellular product itself (typically via the IND pathway, which restricts most allogeneic MSC use to clinical trials), whereas COFEPRIS regulates the establishment, the supplying laboratory, the treating physician, and the advertising as four independently verifiable authorizations.
- Donor screening
- Allogeneic MSCs must be sourced from COFEPRIS-registered laboratories with documented donor consent, infectious disease screening (HIV, HBV, HCV, syphilis, HTLV, CMV minimum), genetic/hereditary screening, and a chain of custody — usually summarized in a per-lot Certificate of Analysis (CoA).
- Aviso Sanitario
- The operating notice that licenses the physical clinic establishment to deliver medical services. Every Mexican regenerative-medicine clinic must hold an active Aviso Sanitario — Regeneris Therapy's is 2323025036X00098 and is publicly verifiable on the COFEPRIS portal.
- Aviso de Publicidad
- A separate COFEPRIS authorization required before a clinic may publish any marketing claim about a health service. Without it, a clinic that advertises regenerative therapy is in violation of COFEPRIS rules — Regeneris Therapy's number is 2323022002A00053.
- Cédula profesional
- The physician's federal license issued by the Secretaría de Educación Pública (SEP), publicly verifiable at cedulaprofesional.sep.gob.mx. Every treating physician in a Mexican clinic must hold an active cédula, and specialists additionally hold a cédula de especialidad.
How COFEPRIS regulates stem cell therapy
Stem cell therapy in Mexico sits at the intersection of several regulatory frameworks. COFEPRIS authorizes the establishment (Aviso de Funcionamiento), supervises the advertising claims a clinic can legally make (Aviso de Publicidad), regulates the laboratories that process the cells (Disposición de Células Troncales), and — through the General Health Law and its regulations on medical care — defines who may legally administer a regenerative protocol.
In practice this means three things for the patient. First, the cells themselves must come from a COFEPRIS-registered tissue or processing facility, with documented donor screening and chain of custody. Second, the clinic that infuses or injects the cells must have an active health notice on file and a designated Responsable Sanitario (health officer) with a verifiable cédula profesional. Third, the physician who performs the procedure must hold an active cédula profesional issued by the Secretaría de Educación Pública (SEP) — Mexico's federal professional licensing authority.
Mexico does not yet have a single, monolithic regulation that covers every regenerative therapy end-to-end the way the FDA's IND framework does in the United States. What it does have is a layered system of NOMs (Normas Oficiales Mexicanas), COFEPRIS rulings, and General Health Law provisions that together establish the floor a legitimate clinic must operate above. The clinics that take patient safety seriously document each layer publicly, on a regulatory page like ours, instead of asking patients to trust an unverifiable claim.
FDA vs COFEPRIS — what is the actual difference?
The most common question from US patients is some version of "if the FDA hasn't approved this therapy, how can it be legal in Mexico?" The honest answer is that the FDA and COFEPRIS use different categorization frameworks for cellular products — neither agency is more or less strict in the absolute sense, but they draw the line in different places.
Three differences that matter to patients
- Investigational vs authorized practice. Most allogeneic stem cell products in the United States sit inside the FDA's IND (Investigational New Drug) pathway, which means they can only be administered inside a registered clinical trial. In Mexico, COFEPRIS allows physicians to use mesenchymal stem cell preparations from authorized laboratories as part of medical practice, provided the clinic, the lab, and the physician all hold the correct licenses.
- Where the regulation lives. FDA regulation centers on the product (the biologic itself goes through approval). COFEPRIS regulation centers on the establishment and the supply chain: the clinic, the lab, the physician, and the advertising material each carry an authorization, and patients can verify each one independently.
- Advertising and patient claims. COFEPRIS requires an explicit Aviso de Publicidad before a clinic can publish marketing claims about a regenerative therapy. There is no equivalent FDA pre-clearance for clinic marketing in the United States — which is why so many US patients encounter aggressive claims online from clinics that would not be allowed to advertise the same way in Mexico.
Patients sometimes assume "FDA-approved" is the global gold standard. In a country where the FDA has no jurisdiction, the question that actually protects you is whether the Mexican clinic in front of you is operating inside the rules its own regulator has written — and whether you can verify it.
Is COFEPRIS internationally recognized?
For patients travelling from the United States or Canada, a fair question is whether COFEPRIS is a serious regulator or a rubber stamp. The answer is documented at the regional level: in 2012 the Pan American Health Organization (PAHO), the World Health Organization's office for the Americas, formally recognized COFEPRIS as a National Regulatory Authority of Regional Reference for medicines and biological products — a status awarded only after an evaluation of the agency's core regulatory functions for ensuring the quality, safety, and efficacy of medical products.
COFEPRIS sits inside PAHO/WHO's group of National Regulatory Authorities of Regional Reference (NRAr) alongside the U.S. Food and Drug Administration (FDA), Health Canada, Brazil's ANVISA, Argentina's ANMAT, and other leading agencies in the Americas. In other words, the regulator overseeing a properly licensed Mexican clinic is a peer of the regulators US and Canadian patients already trust at home. This recognition does not mean any individual clinic is automatically safe — that still depends on the clinic-level checks described above — but it does mean the regulatory floor is set by an internationally peer-reviewed authority, not an improvised one.
References for this section
Planning treatment as an international patient
Most patients who consider stem cell therapy in Cancún are travelling from another country, and a safe experience is as much about logistics and continuity of care as it is about the procedure itself. A legitimate clinic structures the journey so that the clinical decisions happen before you fly, not after you arrive. That begins with a remote medical evaluation: you share your diagnosis, imaging, and relevant history, and a licensed physician determines whether your case is a reasonable candidate and what — if anything — can be offered, in writing, before you commit to travel.
Pre-arrival screening protects both you and the standard of care. Depending on your case, the treating physician may request recent laboratory work or imaging before confirming a plan, so that contraindications are identified early rather than discovered on the day of a procedure. Cancún International Airport (CUN) has direct flights from most major US and Canadian cities, and the city is an established medical-tourism hub with bilingual hospitals for the rare event that escalation of care is needed; a responsible clinic will tell you which facility it partners with.
Continuity of care after you return home is the part under-regulated operators most often ignore. With your written consent, a serious clinic shares a procedure summary, the cell-product Certificate of Analysis details, and a post-procedure plan with your physician at home, so follow-up and monitoring are coordinated by someone who knows your full medical picture. Your home doctor keeps independent clinical judgment; the clinic's job is to make sure they have the documentation they need. We treat coordination with your existing physician as a feature of legitimate care, never a threat to it.
How to verify a clinic's COFEPRIS authorization
Every COFEPRIS authorization is a public record. Before paying a deposit for stem cell therapy in Mexico, take twenty minutes and confirm the following five things with the clinic in writing:
- Ask for the Aviso de Funcionamiento number. This is the operating notice for the physical establishment. It is a long alphanumeric string (ours is 2323025036X00098). The clinic should publish it on a dedicated regulatory page, not just say the words "COFEPRIS regulated" in a paragraph somewhere.
- Ask for the Aviso de Publicidad number. This is the advertising notice that authorizes the clinic to make marketing claims about regenerative therapy. A clinic that lacks this notice but publishes treatment claims is, strictly speaking, advertising in violation of COFEPRIS rules — which is itself a warning sign.
- Ask who the Responsable Sanitario is. Every Mexican medical establishment must designate a health officer — a licensed physician who is legally accountable for the clinic's compliance. The clinic should be willing to name this person and provide their cédula profesional.
- Verify the treating physician's cédula profesional. Take the cédula number for the physician who would actually administer the protocol and check it yourself at cedulaprofesional.sep.gob.mx. The SEP registry is free, public, and authoritative. If the physician cannot or will not provide a cédula, walk away.
- Ask where the cells come from. The clinic should be able to name the COFEPRIS-registered laboratory that supplies the stem cell preparations and describe its donor screening protocol. Vague answers ("we have our own lab", "the cells are imported") without a registered facility name are a flag.
The official COFEPRIS portal is available at gob.mx/cofepris and the SEP National Registry of Professionals at cedulaprofesional.sep.gob.mx.
Regeneris Therapy COFEPRIS credentials
We publish our own regulatory footprint in full so you can verify everything before your first call.
Our public regulatory record
Aviso de Funcionamiento (Operating Notice)
2323025036X00098
Aviso de Publicidad (Advertising Notice)
2323022002A00053
Legal name
Regeneris Therapy
Health Officer (Responsable Sanitario)
Dr. Misael González Montenegro · Cédula 13226492
Medical Director
Dra. Marian Tufano · Cédula 12353680
Establishment
Av. Tulúm SM 11 MZ 1 Lote 1 Local 207, Cancún, Quintana Roo 77504
See the full regulatory page · Meet the physicians with verifiable cédulas
Donor screening and lab accreditation requirements
The donor screening protocol for allogeneic mesenchymal stem cells (MSCs) is one of the strongest safety filters in regenerative medicine — and one of the easiest places for an under-regulated clinic to cut corners. A legitimate Mexican supply chain mirrors the international standards published by organizations like ISCT and AABB, and is documented at the laboratory that processes the cells, not at the clinic that infuses them.
A compliant donor pipeline involves explicit informed consent from the donor, infectious disease screening (HIV, HBV, HCV, syphilis, HTLV, CMV at minimum, with additional regional tests depending on the donor's geography), genetic and hereditary disease screening, and a documented chain of custody from collection through cryopreservation and shipment. The receiving clinic should be able to produce a Certificate of Analysis (CoA) for each lot before infusion, listing the donor screening results, cell viability, surface marker characterization (CD90+/CD73+/CD105+ for MSCs), and absence of contamination.
Lab accreditation in Mexico is administered by COFEPRIS through the Comisión de Autorización Sanitaria, with additional sector standards under NOM-253-SSA1-2012 for the disposition of human blood and its components. Laboratories that supply cellular preparations to clinics must hold an active operating license and are subject to periodic inspection. International accreditations — ISO 9001 for quality management, ISO 13485 for medical devices, NB-MED for biologics — are common in the better facilities and worth asking about.
References for this section
- ISCT — Minimal criteria for defining multipotent mesenchymal stromal cells (Dominici et al., Cytotherapy 2006)
- AABB / FACT-JACIE — Standards for cellular therapy product collection, processing & donor eligibility
- NOM-253-SSA1-2012 — Para la disposición de sangre humana y sus componentes con fines terapéuticos (Diario Oficial de la Federación)
What the peer-reviewed evidence says about safety
Conservatively summarized, the published safety record for allogeneic mesenchymal stromal/stem cell (MSC) therapy is favorable, but it is not zero-risk and outcomes are not guaranteed. A 2012 meta-analysis in PLoS ONE that pooled 36 randomized and non-randomized trials found no association between MSC administration and acute infusional toxicity, organ-system complications, infection, death, or malignancy — the only adverse event significantly associated with treatment was transient fever. Most reported reactions are mild and self-limiting, such as low-grade fever, headache, or temporary soreness at an injection site.
More recent systematic reviews echo this pattern while urging caution: serious adverse events directly attributable to properly screened, properly administered MSCs are uncommon, but the long-term evidence base is still maturing and the quality of source cells and clinical oversight matter enormously. This is precisely why the regulatory checks described above — a COFEPRIS-registered supplying laboratory, documented donor screening, and a licensed treating physician — are not bureaucratic box-ticking but the mechanism by which the favorable safety profile observed in trials is actually reproduced in a real clinic.
We deliberately do not publish a single headline 'success rate' or guarantee. Reputable bodies, including the U.S. FDA and the International Society for Cell & Gene Therapy (ISCT), warn patients to be skeptical of clinics that promise cures or quote outcome statistics for conditions where the evidence does not yet support them. A clinic operating in good faith presents the evidence as it stands — promising for many musculoskeletal and inflammatory indications, still investigational for others — and sets expectations through an individual medical evaluation rather than a marketing number.
References for this section
- Lalu MM, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis. PLoS ONE 2012;7(10):e47559 (PMC).
- Thompson M, et al. Cell therapy with intravascular administration of MSCs: an updated systematic review & meta-analysis. EClinicalMedicine 2020 (PMC).
- U.S. FDA — Consumer warning: be wary of stem cell therapies that are not FDA-approved
Which conditions can legally be treated — and which are investigational
A question every careful patient should ask is not just "is this legal in Mexico?" but "is my specific condition a reasonable, evidence-supported use of stem cell therapy, or is it still experimental?" Under the COFEPRIS framework, a licensed physician may use authorized MSC preparations as part of medical practice, but that legal latitude is not a clinical endorsement of every possible indication. The two questions are separate, and a responsible clinic keeps them separate.
In broad terms, the strongest published evidence base for MSC therapy sits in musculoskeletal and inflammatory contexts — for example knee osteoarthritis and certain orthopedic and degenerative joint conditions — where multiple controlled trials and meta-analyses exist. Other applications remain genuinely investigational, meaning the science is promising but not yet settled, and should be described to you that way, in writing, before any commitment. Mexico does not maintain a single public 'approved indications' list for cellular therapy the way a drug formulary works; instead, the appropriateness of a given indication is a medical judgment made by your treating physician based on your diagnosis, your history, and the current literature.
For this reason, Regeneris does not promise that any particular diagnosis will benefit. Whether your condition is an appropriate candidate is determined during a free medical evaluation, after which you receive an individualized written assessment. If the evidence does not support treatment for your case, the honest answer is part of the standard of care.
Related explainers on this site:
- Mesenchymal stem cells (MSCs) explained
- Umbilical-cord stem cells
- Autologous vs allogeneic — what is the difference?
- How to choose a stem cell clinic (safety checklist)
- Mexico vs USA — FDA and COFEPRIS compared
References for this section
Red flags to avoid in international stem cell clinics
The international medical tourism market for stem cell therapy attracts both legitimate clinics and a long tail of underqualified operators. The pattern is consistent enough that a short checklist filters out most of the worst:
- No COFEPRIS numbers anywhere on the website. A clinic that calls itself "COFEPRIS regulated" but does not publish its actual Aviso de Funcionamiento number is either negligent about transparency or hoping you will not ask. The number is required and is not confidential.
- Refuses to name the supplying laboratory. If the clinic cannot or will not name the COFEPRIS-registered lab that processes the cells, you are being asked to trust a black box. Reputable suppliers in Mexico are happy to be named.
- Treatment plan with no physician evaluation. A protocol that is quoted by a sales representative over WhatsApp without a prior medical consultation with a licensed physician is, by definition, outside the standard of care. Walk away.
- Guaranteed cures or 'always works' language. Mesenchymal stem cell therapy is supportive and evolving. No legitimate clinic guarantees outcomes — and the COFEPRIS advertising rules prohibit that kind of claim. Marketing that promises certainty is non-compliant on its face.
- Cell counts that drift wildly between quotes. A serious protocol specifies the cell type, the cell count, the route of administration, and the source laboratory in writing. If the numbers change from quote to quote, the documentation is not real.
- No written informed consent before payment. Mexican law (NOM-004-SSA3-2012) requires written informed consent for any relevant medical procedure. A clinic that collects a deposit before any consent paperwork is non-compliant before you have even arrived.
Frequently asked questions
Yes. Stem cell therapy is legal in Mexico when it is delivered by a clinic that holds an active COFEPRIS Aviso de Funcionamiento, sources the cells from a COFEPRIS-registered laboratory, and is administered by a physician with an active cédula profesional issued by the SEP. Each of these credentials is publicly verifiable.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
COFEPRIS — Comisión Federal para la Protección contra Riesgos Sanitarios — is Mexico's federal health authority and is the regulatory equivalent of the FDA in the United States. Both operate under their respective Ministries of Health. They use different frameworks for cellular products: the FDA regulates the biologic as a product, while COFEPRIS regulates the establishment, the laboratory, the advertising, and the physician separately. Neither is universally stricter — they draw the line in different places.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Ask the clinic for two specific numbers: the Aviso de Funcionamiento (operating notice for the establishment) and the Aviso de Publicidad (authorization to publish marketing claims). A compliant clinic publishes both on a dedicated regulatory page. You can also report or query COFEPRIS directly through gob.mx/cofepris.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Most allogeneic mesenchymal stem cell preparations are not FDA-approved as drugs in the United States — they sit inside the FDA's IND (Investigational New Drug) pathway and may only be administered inside registered clinical trials. The FDA framework does not apply outside US jurisdiction. In Mexico, equivalent products are administered under COFEPRIS-regulated medical practice, provided the clinic, lab, and physician all hold the correct authorizations.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Safety in Cancún depends on the specific clinic, not the city. The protections that matter — COFEPRIS authorization, an accredited supplying laboratory, a Responsable Sanitario with a verifiable cédula, and written informed consent under NOM-004 — are clinic-level requirements that an international patient can audit before booking. Cancún itself is a major medical-tourism hub with direct flights to most US cities and established bilingual hospitals.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
At minimum, an active cédula profesional issued by the Secretaría de Educación Pública (SEP), verifiable at cedulaprofesional.sep.gob.mx. Specialist physicians additionally hold a cédula de especialidad. Every cédula number on our team page links to the public SEP registry so you can verify independently.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Every Mexican medical establishment must designate a Responsable Sanitario — a licensed physician who is legally accountable for the clinic's compliance with health regulations. In addition, patients have recourse to COFEPRIS (sanitary complaints), CONAMED (the National Medical Arbitration Commission), and the courts. Our regulatory page documents the relevant contact channels.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Allogeneic mesenchymal stem cells are sourced from screened donors at COFEPRIS-registered laboratories. Standard screening covers infectious disease panels (HIV, HBV, HCV, syphilis, HTLV, CMV at minimum), genetic and hereditary disease screening, and documented chain of custody. The receiving clinic should provide a Certificate of Analysis (CoA) for each lot, listing viability and surface marker characterization.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Yes. The Aviso de Publicidad is a separate authorization specifically for health-related marketing. A clinic that publishes treatment claims without it is in violation of COFEPRIS rules — which is itself a useful warning signal when evaluating clinics.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Ask for the clinic's Aviso de Funcionamiento and Aviso de Publicidad numbers in writing. Verify the treating physician's cédula profesional at cedulaprofesional.sep.gob.mx. Ask which COFEPRIS-registered laboratory supplies the cells. Confirm there is a medical consultation before any payment, and that informed consent is provided in writing before any procedure.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
The published safety record is favorable but not zero-risk, and no honest clinic guarantees outcomes. The largest pooled safety analysis to date (Lalu et al., PLoS ONE 2012, a systematic review and meta-analysis of 36 trials) found no significant association between mesenchymal stem cell administration and acute toxicity, organ-system complications, infection, malignancy, or death — the only adverse event significantly linked to treatment was transient fever. Most reported reactions are mild and self-limiting, such as low-grade fever, headache, or temporary injection-site soreness. The long-term evidence base is still maturing, which is exactly why a COFEPRIS-registered supplying laboratory, documented donor screening, and a licensed physician matter: they are how the favorable trial safety profile is reproduced in a real clinic.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
There is no single answer because recovery depends on the route of administration, the indication, and your individual health. Many patients receiving an intravenous infusion or a simple joint injection resume light activity within a day or two, and most reported side effects (mild fever, fatigue, or soreness at an injection site) are temporary. Your treating physician will give you a personalized recovery timeline and clearance-to-travel guidance in writing as part of your plan. Because we cannot promise outcomes or a fixed timeline, the responsible answer is that your post-procedure window is set during your medical evaluation, not pre-quoted by a salesperson.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Yes — we encourage it, and our international-patients program is built around this. With your written consent we can share a procedure summary, the cell-product Certificate of Analysis details, and the post-procedure plan with your physician at home so that follow-up and monitoring are coordinated. Your home physician retains independent clinical judgment; our role is to make sure they have the documentation they need. Continuity of care with your existing doctor is a feature of a legitimate clinic, not a threat to it.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Permanent adverse effects from properly screened, properly administered allogeneic mesenchymal stem cells are uncommon in the published literature; the most frequently reported reactions are temporary, such as low-grade fever, headache, or injection-site soreness. That said, no medical procedure is entirely without risk, the long-term evidence base is still maturing, and individual factors matter — which is why a documented donor-screening chain, a Certificate of Analysis per lot, and written informed consent under NOM-004-SSA3-2012 exist. Your treating physician will review the specific risks for your case in writing before you consent. We do not guarantee that the procedure will be free of side effects.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Autologous cells come from your own body; allogeneic cells come from a screened third-party donor (for mesenchymal stem cells, frequently umbilical-cord tissue donated after a healthy, full-term birth). Under the COFEPRIS framework both pathways require a licensed establishment and physician, but allogeneic cells add a critical layer: they must be processed and screened at a COFEPRIS-registered laboratory with documented donor consent, infectious-disease screening (HIV, HBV, HCV, syphilis, HTLV, CMV at minimum), and a chain of custody summarized in a per-lot Certificate of Analysis. Allogeneic umbilical-cord-derived MSCs are valued because the cells are young, consistently characterized, and available without an additional harvesting procedure on the patient. The choice of cell type for any given case is a medical decision made during your evaluation.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Under the COFEPRIS framework a licensed physician may use authorized mesenchymal stem cell preparations as part of medical practice, but legal latitude is not the same as a clinical endorsement of every indication, and Mexico does not publish a single 'approved indications' list for cellular therapy. The strongest published evidence base sits in musculoskeletal and inflammatory contexts — for example knee osteoarthritis and certain degenerative joint conditions — while many other applications remain genuinely investigational and must be described to you that way, in writing. For that reason we do not promise that any particular diagnosis will benefit. Whether your specific condition is an appropriate, evidence-supported candidate is determined during a free medical evaluation, after which you receive an individualized written assessment; if the evidence does not support treatment for your case, saying so is part of the standard of care.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
In most cases, no. The large majority of US, Canadian, and international health plans classify allogeneic stem cell therapy for musculoskeletal and similar indications as elective or investigational and do not reimburse it, whether it is performed in Mexico or anywhere else. Some patients use medical-financing arrangements or health savings accounts where eligible, but you should confirm specifics directly with your own insurer before assuming coverage. Our model is a free medical evaluation followed by a personalized written quote, so you understand exactly what is involved before any commitment; our team can also provide the procedure documentation some patients submit to their insurer for out-of-network consideration.
Revisado por Dra. Claudia Labastida Salazar · 2026-05-27
Common questions — semantic answers
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
- Is stem cell therapy legal in Mexico?
- Yes. Stem cell therapy is legal in Mexico when it is delivered by a clinic that holds an active COFEPRIS Aviso de Funcionamiento, sources the cells from a COFEPRIS-registered laboratory, and is administered by a physician with an active cédula profesional issued by the SEP. Each of these credentials is publicly verifiable.
- What is COFEPRIS and is it the same as the FDA?
- COFEPRIS — Comisión Federal para la Protección contra Riesgos Sanitarios — is Mexico's federal health authority and is the regulatory equivalent of the FDA in the United States. Both operate under their respective Ministries of Health. They use different frameworks for cellular products: the FDA regulates the biologic as a product, while COFEPRIS regulates the establishment, the laboratory, the advertising, and the physician separately. Neither is universally stricter — they draw the line in different places.
- How do I verify a clinic's COFEPRIS authorization?
- Ask the clinic for two specific numbers: the Aviso de Funcionamiento (operating notice for the establishment) and the Aviso de Publicidad (authorization to publish marketing claims). A compliant clinic publishes both on a dedicated regulatory page. You can also report or query COFEPRIS directly through gob.mx/cofepris.
- Are mesenchymal stem cells FDA-approved?
- Most allogeneic mesenchymal stem cell preparations are not FDA-approved as drugs in the United States — they sit inside the FDA's IND (Investigational New Drug) pathway and may only be administered inside registered clinical trials. The FDA framework does not apply outside US jurisdiction. In Mexico, equivalent products are administered under COFEPRIS-regulated medical practice, provided the clinic, lab, and physician all hold the correct authorizations.
- Is stem cell therapy in Cancún safe for international patients?
- Safety in Cancún depends on the specific clinic, not the city. The protections that matter — COFEPRIS authorization, an accredited supplying laboratory, a Responsable Sanitario with a verifiable cédula, and written informed consent under NOM-004 — are clinic-level requirements that an international patient can audit before booking. Cancún itself is a major medical-tourism hub with direct flights to most US cities and established bilingual hospitals.
- What credentials should the treating physician hold?
- At minimum, an active cédula profesional issued by the Secretaría de Educación Pública (SEP), verifiable at cedulaprofesional.sep.gob.mx. Specialist physicians additionally hold a cédula de especialidad. Every cédula number on our team page links to the public SEP registry so you can verify independently.
- Who is responsible if something goes wrong?
- Every Mexican medical establishment must designate a Responsable Sanitario — a licensed physician who is legally accountable for the clinic's compliance with health regulations. In addition, patients have recourse to COFEPRIS (sanitary complaints), CONAMED (the National Medical Arbitration Commission), and the courts. Our regulatory page documents the relevant contact channels.
- How are the cells screened for donor safety?
- Allogeneic mesenchymal stem cells are sourced from screened donors at COFEPRIS-registered laboratories. Standard screening covers infectious disease panels (HIV, HBV, HCV, syphilis, HTLV, CMV at minimum), genetic and hereditary disease screening, and documented chain of custody. The receiving clinic should provide a Certificate of Analysis (CoA) for each lot, listing viability and surface marker characterization.
- Does COFEPRIS pre-approve marketing claims about stem cells?
- Yes. The Aviso de Publicidad is a separate authorization specifically for health-related marketing. A clinic that publishes treatment claims without it is in violation of COFEPRIS rules — which is itself a useful warning signal when evaluating clinics.
- What should I do before booking?
- Ask for the clinic's Aviso de Funcionamiento and Aviso de Publicidad numbers in writing. Verify the treating physician's cédula profesional at cedulaprofesional.sep.gob.mx. Ask which COFEPRIS-registered laboratory supplies the cells. Confirm there is a medical consultation before any payment, and that informed consent is provided in writing before any procedure.
- What is the adverse event rate for properly regulated stem cell therapy?
- The published safety record is favorable but not zero-risk, and no honest clinic guarantees outcomes. The largest pooled safety analysis to date (Lalu et al., PLoS ONE 2012, a systematic review and meta-analysis of 36 trials) found no significant association between mesenchymal stem cell administration and acute toxicity, organ-system complications, infection, malignancy, or death — the only adverse event significantly linked to treatment was transient fever. Most reported reactions are mild and self-limiting, such as low-grade fever, headache, or temporary injection-site soreness. The long-term evidence base is still maturing, which is exactly why a COFEPRIS-registered supplying laboratory, documented donor screening, and a licensed physician matter: they are how the favorable trial safety profile is reproduced in a real clinic.
- How long does recovery take after stem cell therapy, and when can I fly home?
- There is no single answer because recovery depends on the route of administration, the indication, and your individual health. Many patients receiving an intravenous infusion or a simple joint injection resume light activity within a day or two, and most reported side effects (mild fever, fatigue, or soreness at an injection site) are temporary. Your treating physician will give you a personalized recovery timeline and clearance-to-travel guidance in writing as part of your plan. Because we cannot promise outcomes or a fixed timeline, the responsible answer is that your post-procedure window is set during your medical evaluation, not pre-quoted by a salesperson.
- Can my US or Canadian doctor help coordinate my post-procedure care after returning home?
- Yes — we encourage it, and our international-patients program is built around this. With your written consent we can share a procedure summary, the cell-product Certificate of Analysis details, and the post-procedure plan with your physician at home so that follow-up and monitoring are coordinated. Your home physician retains independent clinical judgment; our role is to make sure they have the documentation they need. Continuity of care with your existing doctor is a feature of a legitimate clinic, not a threat to it.
- Are there any permanent side effects from stem cell therapy?
- Permanent adverse effects from properly screened, properly administered allogeneic mesenchymal stem cells are uncommon in the published literature; the most frequently reported reactions are temporary, such as low-grade fever, headache, or injection-site soreness. That said, no medical procedure is entirely without risk, the long-term evidence base is still maturing, and individual factors matter — which is why a documented donor-screening chain, a Certificate of Analysis per lot, and written informed consent under NOM-004-SSA3-2012 exist. Your treating physician will review the specific risks for your case in writing before you consent. We do not guarantee that the procedure will be free of side effects.
- How do allogeneic and autologous stem cells differ under COFEPRIS regulation, and why does Regeneris use allogeneic cells?
- Autologous cells come from your own body; allogeneic cells come from a screened third-party donor (for mesenchymal stem cells, frequently umbilical-cord tissue donated after a healthy, full-term birth). Under the COFEPRIS framework both pathways require a licensed establishment and physician, but allogeneic cells add a critical layer: they must be processed and screened at a COFEPRIS-registered laboratory with documented donor consent, infectious-disease screening (HIV, HBV, HCV, syphilis, HTLV, CMV at minimum), and a chain of custody summarized in a per-lot Certificate of Analysis. Allogeneic umbilical-cord-derived MSCs are valued because the cells are young, consistently characterized, and available without an additional harvesting procedure on the patient. The choice of cell type for any given case is a medical decision made during your evaluation.
- What specific conditions does Regeneris Therapy treat under COFEPRIS authorization?
- Under the COFEPRIS framework a licensed physician may use authorized mesenchymal stem cell preparations as part of medical practice, but legal latitude is not the same as a clinical endorsement of every indication, and Mexico does not publish a single 'approved indications' list for cellular therapy. The strongest published evidence base sits in musculoskeletal and inflammatory contexts — for example knee osteoarthritis and certain degenerative joint conditions — while many other applications remain genuinely investigational and must be described to you that way, in writing. For that reason we do not promise that any particular diagnosis will benefit. Whether your specific condition is an appropriate, evidence-supported candidate is determined during a free medical evaluation, after which you receive an individualized written assessment; if the evidence does not support treatment for your case, saying so is part of the standard of care.
- Can I use health insurance to pay for stem cell therapy in Mexico?
- In most cases, no. The large majority of US, Canadian, and international health plans classify allogeneic stem cell therapy for musculoskeletal and similar indications as elective or investigational and do not reimburse it, whether it is performed in Mexico or anywhere else. Some patients use medical-financing arrangements or health savings accounts where eligible, but you should confirm specifics directly with your own insurer before assuming coverage. Our model is a free medical evaluation followed by a personalized written quote, so you understand exactly what is involved before any commitment; our team can also provide the procedure documentation some patients submit to their insurer for out-of-network consideration.
Information for educational purposes only. Consult our medical team for individualized advice. Outcomes vary by patient and depend on prior medical evaluation.